These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 18250261

  • 1. No evidence of decrease in cognitive function in users of low-dose Ecstasy.
    Krebs TS, Johansen PØ.
    Arch Gen Psychiatry; 2008 Feb; 65(2):236; author reply 236-7. PubMed ID: 18250261
    [No Abstract] [Full Text] [Related]

  • 2. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [Abstract] [Full Text] [Related]

  • 3. Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users.
    Krebs TS, Johansen PØ, Jerome L, Halpern JH.
    Psychol Med; 2009 May; 39(5):876-8. PubMed ID: 19215629
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evidence for selective executive function deficits in ecstasy/polydrug users.
    Fisk JE, Montgomery C.
    J Psychopharmacol; 2009 Jan; 23(1):40-50. PubMed ID: 18515461
    [Abstract] [Full Text] [Related]

  • 7. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
    Indlekofer F, Piechatzek M, Daamen M, Glasmacher C, Lieb R, Pfister H, Tucha O, Lange KW, Wittchen HU, Schütz CG.
    J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
    [Abstract] [Full Text] [Related]

  • 8. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL, Shear PK, Corcoran K.
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [Abstract] [Full Text] [Related]

  • 9. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.
    Daumann J, Till B, Fischermann T, Rezk M, Gouzoulis-Mayfrank E.
    J Psychopharmacol; 2006 Mar; 20(2):236-44. PubMed ID: 16510481
    [Abstract] [Full Text] [Related]

  • 10. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.
    Huxster JK, Pirona A, Morgan MJ.
    J Psychopharmacol; 2006 Mar; 20(2):281-90. PubMed ID: 16510486
    [Abstract] [Full Text] [Related]

  • 11. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC.
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [Abstract] [Full Text] [Related]

  • 12. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction.
    Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, Wagner M.
    J Psychopharmacol; 2006 May; 20(3):373-84. PubMed ID: 16574711
    [Abstract] [Full Text] [Related]

  • 13. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
    Gouzoulis-Mayfrank E, Daumann J.
    J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
    [Abstract] [Full Text] [Related]

  • 14. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL, Luciana M.
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [Abstract] [Full Text] [Related]

  • 15. Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine.
    Kuypers KP, Ramaekers JG.
    J Psychopharmacol; 2005 Nov; 19(6):633-9. PubMed ID: 16272186
    [Abstract] [Full Text] [Related]

  • 16. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.
    de Sola S, Tarancón T, Peña-Casanova J, Espadaler JM, Langohr K, Poudevida S, Farré M, Verdejo-García A, de la Torre R.
    Psychopharmacology (Berl); 2008 Oct; 200(3):425-37. PubMed ID: 18581098
    [Abstract] [Full Text] [Related]

  • 17. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.
    Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ.
    J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds.
    Bedi G, Redman J.
    Psychol Med; 2008 Sep; 38(9):1319-30. PubMed ID: 18226286
    [Abstract] [Full Text] [Related]

  • 20. Ecstasy (MDMA) and memory function: a meta-analytic update.
    Laws KR, Kokkalis J.
    Hum Psychopharmacol; 2007 Aug; 22(6):381-8. PubMed ID: 17621368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.